Journal of Stem Cell Research & Therapy

Jellyfish collagen biomaterials: Next generation collagen for cell culture and med-tech products

7^th Annual Conference on Stem Cell and Regenerative Medicine

August 04-05, 2016 Manchester, UK

Andrew Mearns Spragg

Jellagen Pty Ltd, UK

Scientific Tracks Abstracts: J Stem Cell Res Ther

Abstract:

Jellagen Pty Ltd (JPL) founded in August 2013, is a Med-Tech business exploiting jellyfish to provide the next generation of collagen biomaterials that are safer and more technically versatile than current sources of mammalian derived collagen products for application in 3D cell culture (in vitro diagnostics, including research level regenerative medicine R&D) and medical devices. JPL�??s research grade materials are on market and our vision is to be the leading provider of medical grade nonmammalian collagen products to these markets in addition to conducting in-house development of new medical devices for wound and cartilage repair. Jellagen offers the following next generation collagen products for research application: Research grade acid and enzyme soluble and powdered native collagen; Collagen sponge scaffolds for 3D cell culture; Hydrogels (3D cell culture and tissue engineering application) and; Prototype bio-mimetic collagen membrane medical device products (at pre-clinical stage).

Biography :

Andrew Mearns Spragg is the Co-Founder and CEO of Jellagen Pty Ltd. He has gained a first class honors Degree in Microbiology and a PhD in Marine Biotechnology from Heriot-Watt University, UK. For the past 16 years his career has focused on the creation of companies involved with the commercial exploitation of marine based science and technologies. He has successfully risen over £12.5M in equity finance and has secured competitive grant funding from EU and UK sources worth >£2M. He was the recipient of the 2007 Gannochy Medal from the Royal Society of Edinburgh and his entrepreneurial achievements were recognized through winning the Ernst & Young Entrepreneur of the year 2008 in Health Care for Scotland. He holds honorary chairs from the University of Stirling and Fellowships from the Royal Society of Chemistry and Biology.

Email: andrew@jellagen.co.uk